Corcept Therapeutics Incorporated (CORT)
Corcept Shares Rise More Than 60% in Three Months: Here's Why
CORT's Cushing's syndrome drug, Korlym, is driving revenues. The NDA for relacorilant in Cushing's syndrome will be filed shortly.
3 Reasons Growth Investors Will Love Corcept (CORT)
Corcept (CORT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Wall Street Analysts Think Corcept (CORT) Could Surge 37.91%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 37.9% in Corcept (CORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Corcept (CORT) is on the Move, Here's Why the Trend Could be Sustainable
Corcept (CORT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article.
5 Small Drug Stocks to Buy as Trump Gets Re-Elected
Innovation is at its peak for the Zacks Medical-Drugs industry. MDGL, CORT, CPRX, LRMR and TBPH may prove to be good additions to one's portfolio.
Corcept Therapeutics Stock Surges 61% in 2024: A Must Buy?
Investors should invest in CORT right now as the stock is doing extremely well in 2024 and its prospects look even brighter.
Here is Why Growth Investors Should Buy Corcept (CORT) Now
Corcept (CORT) could produce exceptional returns because of its solid growth attributes.
Corcept (CORT) Upgraded to Strong Buy: Here's Why
Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Best Momentum Stocks to Buy for November 5th
CORT, ZBRA and QUAD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 5, 2024.
Corcept Therapeutics Incorporated (CORT) Soars to 52-Week High, Time to Cash Out?
Corcept (CORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Wall Street Analysts Believe Corcept (CORT) Could Rally 56.66%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 56.7% in Corcept (CORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
